Processa Pharmaceuticals, Inc. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for the quarter ending 2021-06-30 was $300.00K.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for the quarter ending 2020-09-30 was $2.00M.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for the quarter ending 2018-12-31 was -$51.12K.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for the quarter ending 2018-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for fiscal 2024 was $189.00K.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for fiscal 2023 was -$30.61K.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for fiscal 2021 was $173.99K, a 97.77% decline from fiscal 2020.
- Processa Pharmaceuticals, Inc. stock issued during period, value, other for fiscal 2020 was $7.80M.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2024-12-31 | $189.00K 10-K · filed 2026-03-18 | |
| 2023-12-31 | -$30.61K 10-K · filed 2025-03-20 | |
| 2021-12-31 | $173.99K 10-K · filed 2023-03-30 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $7.80M 10-K · filed 2021-03-25 | |
| 2020-09-30 | $2.00M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | -$51.12K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | -$168.46K 10-K · filed 2020-03-06 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | |
| 2018-06-30 | -$117.34K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |